Search Result

Results for "

c-Met kinase inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Met/HGFR (45) Akt (1) Apoptosis (16) Autophagy (3) c-Kit (6) FGFR (1) FLT3 (6) mTOR (1) PDGFR (3) PI3K (1) Polo-like Kinase (PLK) (1) RAD51 (2) Raf (1) RET (3) RIP kinase (1) TAM Receptor (6) Trk Receptor (1) VEGFR (12)
By Research Areas:	Cancer (51) Inflammation/Immunology (1) Metabolic Disease (1)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: c-Met/HGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148279

c-Met-IN-15	c-Met/HGFR	Cancer
c-Met-IN-15 (compound S3) is a **c-Met kinase** inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM .

HY-50686

Tivantinib 10+ Cited Publications ARQ 197; (3R,4R)-ARQ 198	c-Met/HGFR Apoptosis	Cancer
Tivantinib is a highly selective *c-Met* tyrosine kinase inhibitor with a K_i of 355 nM.

HY-116000

Glumetinib 1 Publications Verification Gumarontinib; SCC244	c-Met/HGFR	Cancer
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .

HY-12017

PF-04217903 3 Publications Verification	c-Met/HGFR	Cancer
PF-04217903 is a potent ATP-competitive **c-Met kinase** inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-12017A

PF-04217903 mesylate 3 Publications Verification	c-Met/HGFR	Cancer
PF-04217903 mesylate is a potent ATP-competitive **c-Met kinase** inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 mesylate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-153831

c-Met-IN-17	c-Met/HGFR	Cancer
c-Met-IN-17 is a potent *c-Met* kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II *c-Met* kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-124267

Zgwatinib SOMG-833	c-Met/HGFR	Cancer
Zgwatinib (SOMG-833) is a potent, selective, and ATP-competitive *c-MET* inhibitor, with an IC₅₀ of 0.93 nM against c-MET, over 10,000-fold more potent compared with 19 tyrosine kinases (including c-MET family members and highly homologous kinases). Zgwatinib potently inhibits c-MET-driven cell proliferation. Zgwatinib as a potential candidate agent for c-MET-driven human cancers research .

HY-164394

EMD 1204831	c-Met/HGFR	Cancer
EMD 1204831 is a potent and highly selective *c-Met* inhibitor which selectively suppresses the c-Met receptor tyrosine kinase activity with an IC₅₀ of 9 nM. EMD 1204831 can be utilized in cancer research .

HY-12017B

PF-04217903 phenolsulfonate	c-Met/HGFR	Cancer
PF-04217903 phenolsulfonate is a potent ATP-competitive **c-Met kinase** inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-147259

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective *c-Met* kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

HY-50683

JNJ-38877605 4 Publications Verification	c-Met/HGFR	Metabolic Disease Cancer
JNJ-38877605 is an orally active ATP-competitive inhibitor of *c-Met* with an IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .

HY-150582

c-Met-IN-14	c-Met/HGFR c-Kit FLT3 Apoptosis	Cancer
c-Met-IN-14 (compound 26af) is a selective inhibitor of *c-Met* kinase from N-sulfonylamidine-based derivatives, with an IC₅₀ value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner .

HY-133083

BAY-474	c-Met/HGFR	Cancer
BAY-474 is a tyrosine-protein kinase *c-Met* inhibitor. BAY-474 acts as an epigenetics probe .

HY-13404

Capmatinib 10+ Cited Publications INC280; INCB28060	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404B

Capmatinib hydrochloride INC280 hydrochloride; INCB-28060 hydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404C

Capmatinib dihydrochloride hydrate 10+ Cited Publications INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404A

Capmatinib dihydrochloride INC280 dihydrochloride; INCB28060 dihydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13068

Golvatinib 4 Publications Verification E-7050	c-Met/HGFR VEGFR	Cancer
Golvatinib (E-7050) is a potent dual inhibitor of both *c-Met* and VEGFR2 kinases with IC₅₀s of 14 and 16 nM, respectively.

HY-76688

(Rac)-Tivantinib (Rac)-ARQ 197; (Rac)-ARQ 198	Others c-Met/HGFR	Cancer
(Rac)-Tivantinib is the isomer of Tivantinib (HY-50686), and can be used as an experimental control. Tivantinib is a highly selective *c-Met* tyrosine kinase inhibitor with a K_i of 355 nM.

HY-13404R

Capmatinib (Standard)	c-Met/HGFR Apoptosis	Cancer
Capmatinib (Standard) is the analytical standard of Capmatinib. This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-11107

PHA-665752 10+ Cited Publications	c-Met/HGFR Autophagy Apoptosis	Cancer
PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of *c-Met* kinase (K_i=4 nM; IC₅₀=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases. PHA-665752 induces apoptosis and cell cycle arrest, and exhibits cytoreductive antitumor activity .

HY-123237

KRC-108	c-Met/HGFR FLT3 Trk Receptor Apoptosis Autophagy	Cancer
KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC₅₀s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for *c-Met, c-Met* M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice .

HY-107145

Ningetinib Tosylate	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for *c-Met, VEGFR2* and Axl, respectively.

HY-107145A

Ningetinib	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for *c-Met, VEGFR2* and Axl, respectively.

HY-125017

Bozitinib 1 Publications Verification PLB-1001; CBT-101; Vebreltinib	c-Met/HGFR	Cancer
Bozitinib (PLB-1001) is a highly selective *c-MET* kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .

HY-10991

MGCD-265 analog 1 Publications Verification	c-Met/HGFR VEGFR Apoptosis	Cancer
MGCD-265 analog is a potent and oral active inhibitor of *c-Met* and VEGFR2 tyrosine kinases, with IC₅₀s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity .

HY-13299

MK-8033 2 Publications Verification	c-Met/HGFR	Cancer
MK-8033 is an orally active ATP competitive *c-Met/Ron* dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .

HY-13299A

MK-8033 hydrochloride 2 Publications Verification	c-Met/HGFR	Cancer
MK-8033 hydrochloride is an orally active ATP competitive *c-Met/Ron* dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .

HY-147218

PF-07265807	c-Met/HGFR TAM Receptor	Cancer
PF-07265807 is a potent TAM and *c-Met* kinase inhibitor with IC₅₀ values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer .

HY-146274

c-Met-IN-10	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-10 (compound 26a) is a highly potent **c-Met kinase** inhibitor with an IC₅₀ value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC₅₀s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer .

HY-114356

BPI-9016M	c-Met/HGFR	Cancer
BPI-9016M is a potent, orally active, and selective dual *c-Met* and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma .

HY-18711

SCR-1481B1 free base Metatinib free base; c-Met inhibitor 2 free base	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascular endothelial growth factor receptor 2 (VEGFR2) .

HY-123225

LCRF-0004	c-Met/HGFR	Cancer
LCRF-0004 is a potent inhibitor of RON kinase, with the IC₅₀ value of 10 nM. and a surprising result is also obtained regarding its *c-Met* inhibitory activity, with the IC₅₀ value of 12 nM. LCRF-0004 plays an important role in cancer research .

HY-12044

Cabozantinib S-malate Maximum Cited Publications 41 Publications Verification XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, *c-Met, Kit, Axl* and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-155544

Antitumor agent-111	c-Met/HGFR	Cancer
Antitumor agent-111 (compound 46) is an *c-Met* kinase inhibitor (IC₅₀=46 nM) with antitumor and antiproliferative activity. Antitumor agent-111 arrests cell cycle at G0/G1 phase, and induces apoptosis .

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-77493

(rel)-Tivantinib (rel)-ARQ 197; (rel)-(3R,4R)-ARQ 198	Others	Cancer
(rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC) .

HY-13016S

Cabozantinib-d6 XL184-d₆; BMS-907351-d₆	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-131064

RIPK3-IN-1 1 Publications Verification	RIP kinase	Inflammation/Immunology
RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC₅₀ of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC₅₀s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC₅₀ of 1.1 μM .

HY-10206

Amuvatinib 5+ Cited Publications MP470; HPK 56	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET Apoptosis	Cancer
Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, *c-Met* and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-10206A

Amuvatinib hydrochloride MP470 hydrochloride; HPK 56 hydrochloride	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET	Cancer
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, *c-Met* and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-50687

(3S,4S)-Tivantinib (3S,4S)-ARQ 197; ARQ 198	Others	Cancer
(3S,4S)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (3S,4S)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC) .

HY-124761

Poloppin	Polo-like Kinase (PLK) Autophagy	Cancer
Poloppin is a potent, cell penetrant inhibitor of the *mitotic Polo-like kinase* (PLK) (IC₅₀=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (K_d*= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET* inhibitors .

HY-12076

BMS 777607 5+ Cited Publications BMS 817378	c-Met/HGFR TAM Receptor	Cancer
BMS 777607 (BMS 817378) is a Met-related inhibitor for *c-Met, Axl, Ron* and Tyro3 with IC₅₀s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases .

HY-12423

Pamufetinib TAS-115	VEGFR c-Met/HGFR	Cancer
Pamufetinib (TAS-115) is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC₅₀s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

HY-12423A

Pamufetinib mesylate TAS-115 mesylate	VEGFR c-Met/HGFR	Cancer
Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC₅₀s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

HY-164384

DFX117	PI3K Akt mTOR Apoptosis	Cancer
DFX117 is a selective, orally active inhibitor for PI3Kα and **c-Met tyrosine kinase*. DFX117 inhibits* PI3K/Akt/mTOR pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 with IC₅₀s 0.02-0.08 µM. DFX117 arrests cell cycle at G0/G1 phase, induces apoptosis in A549 and NCI-H1975. DFX117 exhibits antitumor efficacy in mice .

HY-123597

NSC 109555 DDUG; NCI C04808	Others	Cancer
NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC₅₀=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC₅₀ values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC₅₀=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.

HY-118269

OSI-296	c-Met/HGFR	Cancer
OSI-296 is a potent, oral and selective inhibitor of *cMET* and RON kinases. OSI-296 shows in vivo efficacy in MKN45 tumor xenografts models and well tolerated .

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

1,064 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,064 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	Product Name	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Cat. No.	Product Name		Classification

HY-153831

c-Met-IN-17		Alkynes
c-Met-IN-17 is a potent *c-Met* kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: